Subject(s)
Carcinoma, Merkel Cell , Carcinoma, Neuroendocrine , Carcinoma, Squamous Cell , Merkel cell polyomavirus , Polyomavirus Infections , Skin Neoplasms , Soft Tissue Neoplasms , Tumor Virus Infections , Humans , Carcinoma, Merkel Cell/diagnosis , Carcinoma, Merkel Cell/pathology , Skin Neoplasms/diagnosis , Skin Neoplasms/pathology , Polyomavirus Infections/diagnosis , Polyomavirus Infections/pathology , Carcinoma, Squamous Cell/diagnosis , Carcinoma, Squamous Cell/pathology , Tumor Virus Infections/diagnosis , Tumor Virus Infections/pathology , Carcinoma, Neuroendocrine/diagnosisSubject(s)
Humans , Anilides , Carcinoma, Renal Cell/complications , Carcinoma, Renal Cell/drug therapy , Kidney Neoplasms/complications , Kidney Neoplasms/drug therapy , Pyridines , Ulcer , Vasculitis, Leukocytoclastic, Cutaneous/chemically induced , Vasculitis, Leukocytoclastic, Cutaneous/pathologyABSTRACT
Hidradenitis suppurativa (HS) is a chronic, inflammatory, and recalcitrant skin disease of the terminal hair follicle. Therapeutic alternatives in HS are limited nowadays. Adalimumab, is the only approved biological treatment for patients with moderate to severe HS, and some patients do not reach an optimal response, or experience a progressive response loss, needing therapeutic alternatives. IL-23 pathway is also involved in HS pathogenesis, so its blockade could contribute to reach disease control. Guselkumab is a monoclonal antibody targeting the p19 subunit of extracellular IL-23, currently approved for psoriasis in adults, and recently some authors have reported its effectiveness in patients with moderate to severe HS refractory to other systemic treatments, becoming a hope for some patients. However adequate dosing and intervals have not been determined yet, so in most published series, doses approved for psoriasis are commonly used. On this topic a retrospective bicentric study including HS patients treated with guselkumab in the dermatologic departments of university hospitals Puerta de Hierro of Majadahonda (Madrid, Spain) and Doctor Peset of Valencia (Valencia, Spain) was conducted. We reported effectiveness, dosage and frequency of administration in the cohort, in order to establish the most effective dosage regimen and to clarify the potential role of guselkumab for this disease.